Effectiveness of Drug Eluting TACE in Primary HCC

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

the aim of this work to compare effectiveness of drug-eluting bead trans-arterial chemo-embolization and conventional trans-arterial chemo-embolization of hepatic cell carcinoma in the aspect of (Tumor response via m-RECIST criteria), (liver injury via Liver function tests and tumor markers) and (survival outcome) of patients treated in Assiut university .

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Doxorubicin; Ethiodized Oil; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• patients must be 18 to 75 years old.

• patients must be diagnosed as primary Hepatocellular carcinoma (HCC) by radiologic imaging revealed angiogenicity pattern .

• All of the patient have Child-Pugh status A or B .

• All of the patient have BCLC stage A or B.

• patients must have adequate renal and liver function accepting the maneuver.

• patients must have adequate coagulation profile (platelets count ≥ 80 000), (prothrombin concentration ≥ 70 %).

• patients must haven't previous history of resection of other ablation (alcohol, radio frequency or micro wave ablation).

Exclusion Criteria:

• patients have previous history of resection of other ablation (alcohol, radio frequency or micro wave ablation).

• patients with impaired coagulation profile (platelets count < 80 000), (prothrombin concentration < 70 %).

• patients with decompensated liver cell failure having ascites which impedes the maneuver .

• patients with past history of reaction to the drug used in maneuver

• patients with poor image quality.

• patients with lost follow up .